Clinical Trials
24
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)โข Click on a phase to view related trials
An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 155
- Registration Number
- NCT05267574
- Locations
- ๐ฆ๐บ
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
๐ฆ๐บPARC Clinical Research, Adelaide, South Australia, Australia
๐ฆ๐บThe Alfred Hospital, Melbourne, Victoria, Australia
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 213
- Registration Number
- NCT04535609
- Locations
- ๐บ๐ธ
University of California, San Diego, La Jolla, California, United States
๐บ๐ธMyology Institute, University of Florida, Gainesville, Florida, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders
- Conditions
- Fatty Acid Oxidation Disorder
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 61
- Registration Number
- NCT04482049
- Locations
- ๐บ๐ธ
Oregon Health & Science University (OHSU), Portland, Oregon, United States
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธVanderbuilt University Medical Center, Nashville, Tennessee, United States
A Study of the Safety of REN001 in Patients With McArdle Disease
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 19
- Registration Number
- NCT04226274
- Locations
- ๐ช๐ธ
Instituto de Investigaciรณn Hospital 12 de Octubre, Madrid, Spain
๐ฌ๐งNational Hospital for Neurology and Neurosurgery, Queens Square, London, United Kingdom
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 23
- Registration Number
- NCT03862846
- Locations
- ๐ฌ๐ง
Institute of Neurology, University College London, London, United Kingdom
๐ฌ๐งWellcome Centre for Mitochondrial Research, Newcastle Upon Tyne, United Kingdom
- Prev
- 1
- 2
- Next